Fluvoxamine is a SSRI; it is FDA approved for the treatment of obsessive-compulsive disorder however it has recently been used for the treatment of COVID and for the prevention of patients being hospitalized. The mechanism of action of fluvoxamine in the treatment of COVID is that fluvoxamine binds to sigma-1 receptors found on immune cells. This then inhibits the production of the cytokines responsible for the inflammatory process, as seen in viral and other infections.

https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/fluvoxamine/#:~:text=Anti%2DInflammatory%20Effect%20of%20Fluvoxamine,reduced%20production%20of%20inflammatory%20cytokines.